View in EDS

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Authors: Holmes FA; Texas Oncology, P.A., US Oncology Research, Houston, TX, USA. Electronic address: faholmesmd@icloud.com., Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Delaloge S; Institut Gustave Roussy, Villejuif, France., Chia SKL; BC Cancer Agency, Vancouver, BC, Canada., Ejlertsen B; Rigshospitalet, Copenhagen, Denmark., Mansi J; Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom., Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan., Gnant M; Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria., Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium., Barrios CH; Hospital São Lucas, PUCRS, Porto Alegre, Brazil., Silovski T; Department of Oncology, UHC Zagreb, Zagreb, Croatia., Šeparović R; University Hospital for Tumors, University Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia., Bashford A; Auckland Hospital, Auckland, New Zealand., Zotano AG; Instituto Valenciano de Oncologia, València, Spain., Denduluri N; Virginia Cancer Specialists, US Oncology Research, Arlington, VA, USA., Patt D; Texas Oncology - Round Rock, US Oncology Research, Austin, TX, USA., Gokmen E; Ege University Faculty of Medicine, Izmir, Turkey., Gore I; Alabama Oncology, Birmingham, AL, USA., Smith JW 2nd; Northwest Cancer Specialists, P.C., US Oncology Research, Vancouver, VA, USA., Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany and German Breast Group, Neu-Isenburg, Germany., Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Tomašević Z; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Petráková K; Masaryk Memorial Cancer Institute, Brno, Czech Republic., DiPrimeo D; Puma Biotechnology Inc., Los Angeles, CA, USA., Wong A; Puma Biotechnology Inc., Los Angeles, CA, USA., Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain., Chan A; Breast Cancer Research Centre-WA & Curtin University, Perth, Australia.
Corporate Authors: ExteNET Study Group
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 May; Vol. 184, pp. 48-59. Date of Electronic Publication: 2023 Feb 10.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36898233
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Holmes+FA%22">Holmes FA</searchLink>; Texas Oncology, P.A., US Oncology Research, Houston, TX, USA. Electronic address: faholmesmd@icloud.com.<br /><searchLink fieldCode="AU" term="%22Moy+B%22">Moy B</searchLink>; Massachusetts General Hospital Cancer Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Delaloge+S%22">Delaloge S</searchLink>; Institut Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Chia+SKL%22">Chia SKL</searchLink>; BC Cancer Agency, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Ejlertsen+B%22">Ejlertsen B</searchLink>; Rigshospitalet, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Mansi+J%22">Mansi J</searchLink>; Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Iwata+H%22">Iwata H</searchLink>; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Gnant+M%22">Gnant M</searchLink>; Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Buyse+M%22">Buyse M</searchLink>; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.<br /><searchLink fieldCode="AU" term="%22Barrios+CH%22">Barrios CH</searchLink>; Hospital São Lucas, PUCRS, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Silovski+T%22">Silovski T</searchLink>; Department of Oncology, UHC Zagreb, Zagreb, Croatia.<br /><searchLink fieldCode="AU" term="%22Šeparović+R%22">Šeparović R</searchLink>; University Hospital for Tumors, University Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia.<br /><searchLink fieldCode="AU" term="%22Bashford+A%22">Bashford A</searchLink>; Auckland Hospital, Auckland, New Zealand.<br /><searchLink fieldCode="AU" term="%22Zotano+AG%22">Zotano AG</searchLink>; Instituto Valenciano de Oncologia, València, Spain.<br /><searchLink fieldCode="AU" term="%22Denduluri+N%22">Denduluri N</searchLink>; Virginia Cancer Specialists, US Oncology Research, Arlington, VA, USA.<br /><searchLink fieldCode="AU" term="%22Patt+D%22">Patt D</searchLink>; Texas Oncology - Round Rock, US Oncology Research, Austin, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gokmen+E%22">Gokmen E</searchLink>; Ege University Faculty of Medicine, Izmir, Turkey.<br /><searchLink fieldCode="AU" term="%22Gore+I%22">Gore I</searchLink>; Alabama Oncology, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Smith+JW+2nd%22">Smith JW 2nd</searchLink>; Northwest Cancer Specialists, P.C., US Oncology Research, Vancouver, VA, USA.<br /><searchLink fieldCode="AU" term="%22Loibl+S%22">Loibl S</searchLink>; Center for Hematology and Oncology Bethanien, Frankfurt, Germany and German Breast Group, Neu-Isenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Masuda+N%22">Masuda N</searchLink>; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Tomašević+Z%22">Tomašević Z</searchLink>; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.<br /><searchLink fieldCode="AU" term="%22Petráková+K%22">Petráková K</searchLink>; Masaryk Memorial Cancer Institute, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22DiPrimeo+D%22">DiPrimeo D</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wong+A%22">Wong A</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Martin+M%22">Martin M</searchLink>; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Chan+A%22">Chan A</searchLink>; Breast Cancer Research Centre-WA & Curtin University, Perth, Australia.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ExteNET+Study+Group%22">ExteNET Study Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2023 May; Vol. 184, pp. 48-59. <i>Date of Electronic Publication: </i>2023 Feb 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36898233
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ejca.2023.02.002
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 48
    Titles:
      – TitleFull: Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Holmes FA
      – PersonEntity:
          Name:
            NameFull: Moy B
      – PersonEntity:
          Name:
            NameFull: Delaloge S
      – PersonEntity:
          Name:
            NameFull: Chia SKL
      – PersonEntity:
          Name:
            NameFull: Ejlertsen B
      – PersonEntity:
          Name:
            NameFull: Mansi J
      – PersonEntity:
          Name:
            NameFull: Iwata H
      – PersonEntity:
          Name:
            NameFull: Gnant M
      – PersonEntity:
          Name:
            NameFull: Buyse M
      – PersonEntity:
          Name:
            NameFull: Barrios CH
      – PersonEntity:
          Name:
            NameFull: Silovski T
      – PersonEntity:
          Name:
            NameFull: Šeparović R
      – PersonEntity:
          Name:
            NameFull: Bashford A
      – PersonEntity:
          Name:
            NameFull: Zotano AG
      – PersonEntity:
          Name:
            NameFull: Denduluri N
      – PersonEntity:
          Name:
            NameFull: Patt D
      – PersonEntity:
          Name:
            NameFull: Gokmen E
      – PersonEntity:
          Name:
            NameFull: Gore I
      – PersonEntity:
          Name:
            NameFull: Smith JW 2nd
      – PersonEntity:
          Name:
            NameFull: Loibl S
      – PersonEntity:
          Name:
            NameFull: Masuda N
      – PersonEntity:
          Name:
            NameFull: Tomašević Z
      – PersonEntity:
          Name:
            NameFull: Petráková K
      – PersonEntity:
          Name:
            NameFull: DiPrimeo D
      – PersonEntity:
          Name:
            NameFull: Wong A
      – PersonEntity:
          Name:
            NameFull: Martin M
      – PersonEntity:
          Name:
            NameFull: Chan A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2023 May
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1879-0852
          Numbering:
            – Type: volume
              Value: 184
          Titles:
            – TitleFull: European journal of cancer (Oxford, England : 1990)
              Type: main
ResultId 1